Differential Sensitivity to MEK Inhibitors Highlights Distinct Entosis Mechanisms in BxPC3 and MCF7 Cells

Paweł Tyrna1,2, Julia Kostro1, Monika Olszanecka1

  • 1Histology and Embryology Students' Science Association, Department of Histology and Embryology, Faculty of Medicine, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland.

Cells
|October 15, 2025
PubMed

Insights

MEK pathway inhibition significantly reduced entosis in pancreatic cancer cells (BxPC3) but not breast cancer cells (MCF7), indicating cell-type-specific regulation of this cancer cell-in-cell process.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Molecular Biology

Background:

  • Entosis is a cell-in-cell phenomenon crucial in epithelial cancers.
  • It involves cell detachment, adhesion, and internalization, driven by actomyosin contractility.
  • Understanding entosis regulation is key to cancer therapy.

Purpose of the Study:

  • To investigate the effect of MEK pathway inhibition on entosis.
  • To determine if MEK inhibition impacts entosis differently in various cancer cell types.

Main Methods:

  • Utilized a functional assay with differentially stained cell populations to assess entosis.
  • Examined MEK pathway inhibition in BxPC3 (pancreatic) and MCF7 (breast) cancer cell lines.
  • Evaluated pharmacological interventions on inner and outer cells during entosis.

Main Results:

  • MEK inhibition significantly reduced the entotic index in BxPC3 cells.
  • MCF7 cells showed no selective reduction in entosis with MEK inhibitors.
  • BxPC3 cells' reliance on adhesion correlated with reduced entosis upon MEK inhibition.

Conclusions:

  • Entosis regulation is cell-type-specific.
  • MEK pathway inhibition differentially affects entosis in epithelial cancers.
  • Differences may relate to protrusion formation and Ras signaling pathways.

Related Concept Videos